HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
S 1033
has ocular hypotensive activity; structure given in first source
Also Known As:
7-(3,5-dihydroxy-2-(1-octenyl)cyclopentyl)-5-heptenoate sodium salt sesquihydrate; S-1033
Networked:
2
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Lipids: 114793
Fatty Acids: 27405
Unsaturated Fatty Acids: 8236
Eicosanoids: 3262
Prostaglandins: 17100
S 1033: 2
Biological Factors: 2472
Inflammation Mediators: 1113
Autacoids: 276
Eicosanoids: 3262
Prostaglandins: 17100
S 1033: 2
Related Diseases
1.
Neoplasms (Cancer)
08/01/1975 - "
Dilution escape (i.e., tumor rejection after challenge with large inocula, and lethal tumor growth after injection of small inocula of lymphoma cells in allogeneic recipients) occurred in K-I-S-incompatible mice that were inoculated with S-1033 and three drug-treated (5-fluorouracil, cyclophosphamide, and pyrazocarboxamideamino) sublines.
"
2.
Lymphoma (Lymphomas)
08/01/1975 - "
Lymphoma S-1033 and all drug-treated sublines except one were found to be essentially nonimmunogenic for B10 mice.
"
08/01/1975 - "
Large i.v. inocula (10(7) cells) of S-1033 and of the drug-treated sublines, with the possible exception of the cyclophosphamide-treated and dimethyltriazenoimideazolecarboxamide-treated lymphomas, were more effectively rejected by K-I-S- than by S-D-incompatible mice.
"
08/01/1975 - "
Eight sublines of the radiation-induced lymphoma S-1033 of C57BL/10 (hereafter called B10) origin were established by exposing the cells in vivo to eight antineoplastic agents for a number of transplant generations.
"
08/01/1975 - "
Dilution escape (i.e., tumor rejection after challenge with large inocula, and lethal tumor growth after injection of small inocula of lymphoma cells in allogeneic recipients) occurred in K-I-S-incompatible mice that were inoculated with S-1033 and three drug-treated (5-fluorouracil, cyclophosphamide, and pyrazocarboxamideamino) sublines.
"
3.
Glaucoma
11/01/1994 - "
These results indicate that S-1033 has a significant ocular hypotensive effect without substantial adverse effects and the new compound seems to deserve further investigation as a possible anti-glaucoma medication.
"
Related Drugs and Biologics
1.
Fluorouracil (Carac)
2.
Cyclophosphamide (Cytoxan)
3.
Antineoplastic Agents (Antineoplastics)